In silico drug metabolism and pharmacokinetic profiles of natural products from medicinal plants in the Congo basin

PurposeDrug metabolism and pharmacokinetics (DMPK) assessment has come to occupy a place of interest during the early stages of drug discovery today. The use of computer modelling to predict the DMPK and toxicity properties of a natural product library derived from medicinal plants from Central Africa (named ConMedNP). Material from some of the plant sources are currently employed in African Traditional Medicine.MethodsComputer-based methods are slowly gaining ground in this area and are often used as preliminary criteria for the elimination of compounds likely to present uninteresting pharmacokinetic profiles and unacceptable levels of toxicity from the list of potential drug candidates, hence cutting down the cost of discovery of a drug.In the present study, we present an in silico assessment of the DMPK and toxicity profile of a natural product library containing ~3,200 compounds, derived from 379 species of medicinal plants from 10 countries in the Congo Basin forests and savannas, which have been published in the literature. In this analysis, we have used 46 computed physico-chemical properties or molecular descriptors to predict the absorption, distribution, metabolism and elimination and toxicity (ADMET) of the compounds.ResultsThis survey demonstrated that about 45% of the compounds within the ConMedNP compound library are compliant, having properties which fall within the range of ADME properties of 95% of currently known drugs, while about 69% of the compounds have ≤ 2 violations. Moreover, about 73% of the compounds within the corresponding “drug-like” subset showed compliance.ConclusionsIn addition to the verified levels of “drug-likeness”, diversity and the wide range of measured biological activities, the compounds from medicinal plants in Central Africa show interesting DMPK profiles and hence could represent an important starting point for hit/lead discovery.

[1]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.

[2]  John Hodgson,et al.  ADMET—turning chemicals into drugs , 2001, Nature Biotechnology.

[3]  David J Newman,et al.  Natural products as leads to potential drugs: an old process or the new hope for drug discovery? , 2008, Journal of medicinal chemistry.

[4]  Pravin Chaturvedi,et al.  Design principles for orally bioavailable drugs , 1996 .

[5]  Pascal Amoa Onguéné,et al.  CamMedNP: Building the Cameroonian 3D structural natural products database for virtual screening , 2013, BMC Complementary and Alternative Medicine.

[6]  W L Jorgensen,et al.  Prediction of drug solubility from Monte Carlo simulations. , 2000, Bioorganic & medicinal chemistry letters.

[7]  P N Judson,et al.  Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. , 1999, SAR and QSAR in environmental research.

[8]  W. L. Jorgensen,et al.  Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .

[9]  W. Sherman,et al.  Prediction of Absolute Solvation Free Energies using Molecular Dynamics Free Energy Perturbation and the OPLS Force Field. , 2010, Journal of chemical theory and computation.

[10]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[11]  J. Lavandera,et al.  Cheminformatic models to predict binding affinities to human serum albumin. , 2001, Journal of medicinal chemistry.

[12]  M. Butler Natural products to drugs: natural product-derived compounds in clinical trials. , 2005, Natural product reports.

[13]  U Norinder,et al.  Experimental and computational screening models for the prediction of intestinal drug absorption. , 2001, Journal of medicinal chemistry.

[14]  T J Campbell,et al.  HERG K+ channels: friend and foe. , 2001, Trends in pharmacological sciences.

[15]  Gisbert Schneider,et al.  Scaffold diversity of natural products: inspiration for combinatorial library design. , 2008, Natural product reports.

[16]  Supa Hannongbua,et al.  In-silico ADME models: a general assessment of their utility in drug discovery applications. , 2011, Current topics in medicinal chemistry.

[17]  Juan M. Luco,et al.  Prediction of the Brain—Blood Distribution of a Large Set of Drugs from Structurally Derived Descriptors Using Partial Least-Squares (PLS) Modeling. , 2010 .

[18]  Russell O. Potts,et al.  A Predictive Algorithm for Skin Permeability: The Effects of Molecular Size and Hydrogen Bond Activity , 1995, Pharmaceutical Research.

[19]  K. Chibale,et al.  Drug Discovery in Africa: Impacts of Genomics, Natural Products, Traditional Medicines, Insights into Medicinal Chemistry, and Technology Platforms in Pursuit of New Drugs , 2012 .

[20]  Wolfgang Sippl,et al.  Bioactive natural products derived from the Central African flora against neglected tropical diseases and HIV. , 2013, Natural product reports.

[21]  M. Yazdanian,et al.  Correlating Partitioning and Caco-2 Cell Permeability of Structurally Diverse Small Molecular Weight Compounds , 1998, Pharmaceutical Research.

[22]  Tudor I. Oprea Current trends in lead discovery: Are we looking for the appropriate properties? , 2002, J. Comput. Aided Mol. Des..

[23]  H. Mewes,et al.  Can we estimate the accuracy of ADME-Tox predictions? , 2006, Drug discovery today.

[24]  W. L. Jorgensen,et al.  Prediction of drug solubility from structure. , 2002, Advanced drug delivery reviews.

[25]  Elisabetta Poluzzi,et al.  Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus , 2001, European Journal of Clinical Pharmacology.

[26]  W. L. Jorgensen,et al.  Prediction of Properties from Simulations: Free Energies of Solvation in Hexadecane, Octanol, and Water , 2000 .

[27]  R. Hilgenfeld,et al.  Modern Methods of Drug Discovery , 2003, EXS.

[28]  Michael Christiansen,et al.  The genetic basis of long QT and short QT syndromes: A mutation update , 2009, Human mutation.

[29]  W. L. Jorgensen,et al.  The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. , 1988, Journal of the American Chemical Society.

[30]  J. Vederas,et al.  [Drug discovery and natural products: end of era or an endless frontier?]. , 2011, Biomeditsinskaia khimiia.

[31]  Ajay,et al.  Designing libraries with CNS activity. , 1999, Journal of medicinal chemistry.

[32]  Junmei Wang,et al.  Structure – ADME relationship : still a long way to go ? , 2008 .

[33]  J. Tolan,et al.  MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. , 1999, Journal of pharmaceutical sciences.

[34]  Alex M Aronov,et al.  Predictive in silico modeling for hERG channel blockers. , 2005, Drug discovery today.

[35]  Alan L Harvey,et al.  Natural products in drug discovery. , 2008, Drug discovery today.

[36]  H. van de Waterbeemd,et al.  ADMET in silico modelling: towards prediction paradise? , 2003, Nature reviews. Drug discovery.

[37]  E Wanke,et al.  A Novel Role for HERG K+ Channels: Spike‐Frequency Adaptation , 1997, The Journal of physiology.

[38]  J. Vederas,et al.  Drug Discovery and Natural Products: End of an Era or an Endless Frontier? , 2009, Science.

[39]  Philip N. Judson,et al.  Using Absolute and Relative Reasoning in the Prediction of the Potential Metabolism of Xenobiotics , 2003, J. Chem. Inf. Comput. Sci..

[40]  Denis M. Bayada,et al.  Polar Molecular Surface as a Dominating Determinant for Oral Absorption and Brain Penetration of Drugs , 1999, Pharmaceutical Research.

[41]  A. Cavalli,et al.  Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. , 2002, Journal of medicinal chemistry.

[42]  Marcy J. Balunas,et al.  Drug discovery from natural sources , 2006, The AAPS Journal.

[43]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[44]  S. Efange,et al.  Natural products: a continuing source of inspiration for the medicinal chemist , 2002 .

[45]  Sorel Muresan,et al.  Developing a drug-like natural product library. , 2008, Journal of natural products.

[46]  H. Loth Skin permeability. , 1989, Methods and findings in experimental and clinical pharmacology.

[47]  Tudor I. Oprea,et al.  The Design of Leadlike Combinatorial Libraries. , 1999, Angewandte Chemie.

[48]  F. Koehn,et al.  The evolving role of natural products in drug discovery , 2005, Nature Reviews Drug Discovery.

[49]  Corwin Hansch,et al.  QSAR and ADME. , 2004, Bioorganic & medicinal chemistry.

[50]  P. Carrupt,et al.  Molecular fields in quantitative structure–permeation relationships: the VolSurf approach , 2000 .

[51]  Franco Lombardo,et al.  In silico ADME prediction: data, models, facts and myths. , 2003, Mini reviews in medicinal chemistry.

[52]  Stefan Wetzel,et al.  Cheminformatic Analysis of Natural Products and their Chemical Space , 2007 .

[53]  Gisbert Schneider,et al.  Trends in virtual combinatorial library design. , 2002, Current medicinal chemistry.

[54]  Wolfgang Sippl,et al.  Cameroonian medicinal plants: a bioactivity versus ethnobotanical survey and chemotaxonomic classification , 2013, BMC Complementary and Alternative Medicine.

[55]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[56]  Russell O. Potts,et al.  Predicting Skin Permeability , 1992, Pharmaceutical Research.

[57]  Ferenc Darvas,et al.  In Silico and Ex silico ADME approaches for drug discovery. , 2002, Current topics in medicinal chemistry.

[58]  Gisbert Schneider,et al.  Properties and Architecture of Drugs and Natural Products Revisited , 2007 .